Last reviewed · How we verify

Dexmedetomidine 5 mcg

Bahria International Hospital · FDA-approved active Small molecule Quality 2/100

Dexmedetomidine 5 mcg is a Small molecule drug developed by Bahria International Hospital. It is currently FDA-approved. Also known as: Dexmedetomidine 5mcg.

Dexmedetomidine 5 mcg, marketed by Bahria International Hospital, holds a position in the sedative and analgesic market with a key composition patent expiring in 2028. The drug's key strength lies in its established market presence and the protection offered by its patent. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic nameDexmedetomidine 5 mcg
Also known asDexmedetomidine 5mcg
SponsorBahria International Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dexmedetomidine 5 mcg

What is Dexmedetomidine 5 mcg?

Dexmedetomidine 5 mcg is a Small molecule drug developed by Bahria International Hospital.

Who makes Dexmedetomidine 5 mcg?

Dexmedetomidine 5 mcg is developed and marketed by Bahria International Hospital (see full Bahria International Hospital pipeline at /company/bahria-international-hospital).

Is Dexmedetomidine 5 mcg also known as anything else?

Dexmedetomidine 5 mcg is also known as Dexmedetomidine 5mcg.

What development phase is Dexmedetomidine 5 mcg in?

Dexmedetomidine 5 mcg is FDA-approved (marketed).

Related